In Depth Research on US Breast Cancer Therapy Market Opportunity Analysis

"US Breast Cancer Therapy Market Opportunity Analysis" Report Highlight:

* US Breast Cancer Incidence & Prevalence
* US Breast Cancer Therapy Market Overview
* US Breast Cancer Drug Clinical Pipeline by Company & Phase
* US Breast Cancer Drug Clinical Pipeline: 251 Drugs
* Majority Drugs in Phase-II Trials: 73 Drugs
* Marketed Breast Cancer Drugs in US: 32 Drugs
* Breast Cancer Patent Analysis

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-US-Breast-Cancer-Therapy-Market-Opportunity-Analysis.php

Table of Contents

1. US Breast Cancer Incidence & Prevalence

2. US Breast Cancer Therapy Market Overview
2.1 Current Market Scenario
2.2 US Breast Cancer Drug Pipeline Overview

3. US Breast Cancer Therapy Market Dynamics
3.1 Favorable Market Parameters
3.2 Commercialization Challenges

4. US Breast Cancer Therapy Market Future Prospects

5. Mechanism of Breast Cancer Drugs

6. US Breast Cancer Drug Clinical Pipeline by Company & Phase
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-0
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Preregistration
6.11 Registered

7. Marketed Breast Cancer Drug Clinical Insight & Patent Analysis by Company in US
7.1 Albumin-Bound Paclitaxel (Abraxane®)
7.2 Anastrozole (Arimidex®)
7.3 Capecitabine (Xeloda®)
7.4 Docetaxel (Taxotere®)
7.5 Eribulin (Halaven®)
7.6 Everolimus (Afinitor®)
7.7 Exemestane (Aromasin®)
7.8 Fluoxymesterone
7.9 Fulvestrant (Faslodex®)
7.10 Gadobutrol
7.11 Gemcitabine (Gemzar®)
7.12 Goserelin (Zoladex®)
7.13 Ixabepilone (Ixempra®)
7.14 Lapatinib (Tykerb®)
7.15 Letrozole (Femara®)
7.16 Paclitaxel (Taxol®)
7.17 Palbociclib (Ibrance™)
7.18 Pertuzumab (Omnitarg™)
7.19 Pertuzumab Companion Diagnostic (HER2 FISH pharmDx)
7.20 Pertuzumab Companion Diagnostic (HercepTest)
7.21 Raloxifene (Evista®)
7.22 Tamoxifen Oral Liquid (Soltamox®)
7.23 Tc 99m Tilmanocept (Lymphoseek®)
7.24 Technetium Tc 99m Sulfur Colloid Diagnostic Injection
7.25 Temsirolimus (Fareston®)
7.26 Trastuzumab (Herceptin®)
7.27 Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)
7.28 Trastuzumab Companion Diagnostic (HER2 FISH pharmDx)
7.29 Trastuzumab Companion Diagnostic (HercepTest)
7.30 Trastuzumab Emtansine (Kadcyla®)
7.31 Vinorelbine
7.32 Vitamin B12 Fluorescent-Analogues (CobalaFluor Green™, CobalaFluor Red™)

8. Discontinued & Suspended Breast Cancer Drug in Clinical Pipeline in US
8.1 No Development Reported
8.2 Discontinued
8.3 Preregistration-Submission Withdrawal
8.4 Suspended

9. Competitive Landscape
9.1 AbbVie
9.2 Agilent Technologies
9.3 ARIAD Pharmaceuticals
9.4 AstraZeneca
9.5 Bayer
9.6 Biodesix
9.7 BioMarin Pharmaceutical
9.8 Boehringer Ingelheim
9.9 Bristol Mayer Squibb
9.10 Celgene Corporation
9.11 Dako A/S
9.12 Debiopharm
9.13 Dyax
9.14 Eisai
9.15 Eli Lily
9.16 Exelixis
9.17 GalaxoSmithKline
9.18 Incyte Corporation
9.19 Ligand Pharmaceuticals
9.20 Merck
9.21 Navidea Biopharmaceuticals
9.22 Nektar Therapeutics
9.23 Novartis
9.24 Onyx pharmaceuticals
9.25 Pfizer
9.26 Roche
9.27 Sanofi
9.28 Sun Pharmaceuticals

Figure 1-1: US -Estimated Breast Cancer Incidences, 2013-2015
Figure 1-2: US - Estimated Breast Cancer Deaths, 2013-2015
Figure 1-3: US -Estimated Incidences of Female Breast Cancer, 2013-2015
Figure 1-4: US -Estimated Female Breast Cancer Deaths, 2013-2015
Figure 1-5: US -Female Breast Cancer Incidence Compare to Others Cancers, 2015
Figure 1-6: US -Female Breast Cancer Deaths as compared to other Cancers, 2015
Figure 1-7: Diagnosis of Breast Cancer in Different Genders
Figure 1-8: US -Estimated Male Breast Cancer New Cases, 2013-2015
Figure 1-9: US -Estimate Male Breast Cancer Deaths, 2013-2015
Figure 2-1: US - Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-2: US -Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-3: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-4: US -No Development Reported Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-5: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-6: US -Discontinued Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 2-7: US - Suspended Breast Cancer Drug in Clinical Pipeline by Phase (%), 2015
Figure 2-8: US -Suspended Breast Cancer Drug in Clinical Pipeline by Phase (Number), 2015
Figure 3-1: US Breast Cancer Market Drivers
Figure 3-2: US Breast Cancer Therapy Market Commercialization Challenges
Figure 5-1: Type of Breast Cancer Treatment
Figure 5-2: Type of Breast Cancer Surgery
Figure 5-3: Mechanism of Trastuzumab
Figure 5-4: Mechanism of Docetaxel
Figure 5-5: Mechanism of Tamoxifen
Figure 9-1: AbbVie-Clinical Pipeline
Figure 9-2: ARIAD-Clinical Pipeline
Figure 9-3: Celgene Clinical Pipeline
Figure 9-4: Debiopharm-Clinical Pipeline
Figure 9-5: Eisai-Clinical Pipeline

Table 1-1: US -Estimated Number of New Cases for Female Breast Cancer by State, 2015
Table 1-2: US -Estimated Number of Deaths for Breast Cancer by State, 2015

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.